Professor of Bioengineering
University of California
San Francisco, California
Seeking to identify biomarkers from clinical trial samples to inform strategies to reduce morbidity and mortality from breast cancer.
Analyses of clinical trial data is conducted to identify biomarkers of drug resistance in triple-negative breast cancer (TNBC).
These studies will help to improve treatment for patients with TNBC by identifying predictive factors of response to therapy.
The National Cancer Institute-designated Alliance for Clinical Trials in Oncology (Alliance) has a long and successful history of conducting clinical trials in the adjuvant and metastatic setting that aim to reduce morbidity and mortality from breast cancer. BCRF has provided critical support for the molecular analysis of tumor specimens from these clinical trials. These efforts are critically important for the development of biomarkers that can predict risk of recurrence, as well as the identification of new treatment for drug-resistant tumors.
Dr. Kroetz continues her work with BCRF colleagues Monica Bertagnolli and Terry Hyslop to conduct analyses within phase III trials of the Alliance. In a study in advanced estrogen receptor (ER) positive breast cancers, the investigators will identify subgroups of patients who may benefit from anti-estrogen therapy alone versus the addition of a second targeted therapy, bevacizumab.
In a separate analysis of four recently completed breast cancer studies, they hope to identify genetic factors responsible for peripheral neuropathy, a major side effect of a commonly used class of chemotherapy drugs called taxanes.
Deanna Kroetz, PhD, is Professor of Bioengineering in the School of Pharmacy at University of California, San Francisco. Since 2009, she has been a Member of UCSF’s Helen Diller Family Comprehensive Cancer Center. She serves as Member of the Scientific Advisory Board at Arête Therapeutics, Inc. Dr. Kroetz studied pharmacy as an undergraduate at Ohio State University and received her PhD in pharmaceutics at the University of Washington. In 2008, she was elected Fellow of the American Association of Pharmaceutical Scientists. A major goal of her laboratory is to understand the role of genetic variation in determining drug response and toxicity. Integrated genomic and functional studies are focused on identifying genetic biomarkers of taxane-induced sensory peripheral neuropathy and response to anti-retroviral therapies.